Evidence map›Paper›PMID 41972139›Full record

ArticleFrontiers in immunology2026

Correction: Tumor

Takashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, Shingo Nakayama, Yosuke Sasaki, Satoshi Muto, Katsuaki Ieguchi, Makoto Watanabe, Akashi Taguchi, Daisuke Takayanagi and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Takashi ShimizuDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Ryotaro OhkumaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Mayumi HommaDepartment of Pathology, Showa Medical University School of Medicine, Tokyo, Japan.
Shingo NakayamaDepartment of Pathology, Showa Medical University School of Medicine, Tokyo, Japan.
Yosuke SasakiDepartment of Pathology, Showa Medical University School of Medicine, Tokyo, Japan.
Satoshi MutoDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Katsuaki IeguchiDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Makoto WatanabeDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Akashi TaguchiIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Daisuke TakayanagiDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Youichiro WadaIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Atsushi HoriikeDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Yutaro KubotaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Hirotsugu AriizumiDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Masahiro ShimokawaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Yuya HirasawaDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Tomoyuki IshiguroDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Risako SuzukiDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Nana IriguchiDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Emiko MuraDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo, Japan.
Kiyoshi YoshimuraClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Mayumi TsujiDepartment of Pharmacology, School of Medicine, Showa Medical University, Tokyo, Japan.
Yuji KiuchiDepartment of Pharmacology, School of Medicine, Showa Medical University, Tokyo, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Toshiko YamochiDepartment of Pathology, Showa Medical University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1528594.].

Indexed as

biomarkerimmunecheckpoint inhibitorsimmunohistochemistryPD-L1tumor Akkermansia muciniphila

Identifiers

PMID41972139
PMCPMC13062981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.